Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation
Authors:
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 47, 128168
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapyNature, 2012
- Shock and killNature, 2012
- Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2Journal of Virology, 2011
- Establishment of HIV Latency in Primary CD4+Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb RestrictionJournal of Virology, 2010
- HDAC expression and clinical prognosis in human malignanciesCancer Letters, 2009
- Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic PropertiesJournal of Medicinal Chemistry, 2009
- Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into LatencyJournal of Virology, 2008
- SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2)Bioorganic & Medicinal Chemistry Letters, 2008
- Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cellsNature Medicine, 2003
- What's Up and Down with Histone Deacetylation and Transcription?Cell, 1997